About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№1

Consensus statement on the results of the Interdisciplinary Expert Council meeting with international participation on personalized prescription of hormone replacement therapy/menopausal hormone therapy in women at different age periods

DOI
https://dx.doi.org/10.18565/aig.2026.15

A significant decrease in estrogen levels due to the onset of menopause is the cause of the development of clinically significant symptoms of climacteric syndrome, which significantly impair the quality of life, and also refers to factors that increase long-term cardiometabolic risks. According to the current Russian clinical recommendations, menopausal hormone therapy (MHT) is considered as the most effective method for the correction of climacteric disorders.
An Interdisciplinary Expert Council was convened in the last quarter of 2025 to study the topical issues of managing patients in the peri-and postmenopausal periods and the specifics of prescribing MHT in various clinical situations, the main task of which was to optimize scientifically based algorithms for the management of patients with climacteric/postovariectomy syndromes. Based on the results of work by national and international specialists representing various fields of medicine, a consensus document was approved regulating the principles for prescribing HRT/MHT to women with concomitant somatic pathology.

For citation: Consensus statement on the results of the Interdisciplinary Expert Council meeting with 
international participation on personalized prescription of hormone replacement therapy/
menopausal hormone therapy in women at different age periods.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (1): 130-146 (in Russian)
https://dx.doi.org/10.18565/aig.2026.15

Keywords

menopausal hormone therapy
menopause
climacteric syndrome
cardiovascular diseases
metabolic diseases
interdisciplinary council
Full text (in Russian)

References

  1. Delanerolle G., Phiri P., Elneil S., Talaulikar V., Eleje G.U., Kareem R. et al.; MARIE collaborative. Menopause: a global health and wellbeing issue that needs urgent attention. Lancet Glob. Health. 2025; 13(2): e196-e198. https://dx.doi.org/10.1016/S2214-109X(24)00528-X
  2. WНО. Menopause. 2024. Available at: www.who.int/news-room/fact-sheets/detail/menopause
  3. Burki T. Rossella Nappi: taking the stigma out of menopause. Lancet Diabetes Endocrinol. 2023; 11(4): 232. https://dx.doi.org/10.1016/S2213-8587(23)00057-8
  4. Thavabalan K., Ovenell A., Pierce P., Sutaria A., Parkhouse A., Baydemir N. et al. Barriers to the safe discussion of the experience and management of menopausal symptoms: A systematic literature review. Maturitas. 2025; 201: 108683. https://dx.doi.org/10.1016/j.maturitas.2025.108683
  5. Сметник А.А., Иванов И.А., Ермакова Е.И., Табеева Г.И. Особенности использования менопаузальной гормональной терапии в России: результаты масштабного опроса женщин в пери- и постменопаузе. Акушерство и гинекология. 2025; 8: 196-208. [Smetnik A.A., Ivanov I.A., Ermakova E.I., Tabeeva G.I. Characteristics of menopausal hormone therapy use in Russia: results of a large-scale survey of peri- and postmenopausal women. Obstetrics and Gynecology. 2025; (8): 196-208 (in Russian)]. https://dx.doi.org/10.18565/aig.2025.200
  6. Panay N., Fenton A., Hamoda H., Hillard T., Islam R., Pedder H. et al.; (IMS Publication Steering Committee) and The IMS Recommendations Writing Group; IMS Recommendations Writing Group; With valuable support provided by. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025; 28(6): 634-656. https://dx.doi.org/10.1080/13697137.2025.2585487
  7. Johansson T., Karlsson T., Bliuc D., Schmitz D., Ek W.E., Skalkidou A. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024; 387: e078784. https://dx.doi.org/10.1136/bmj-2023-078784
  8. Xia W., Khalil R.A. Hormone replacement therapy and cardiovascular health in postmenopausal women. Int. J. Mol. Sci. 2025; 26(11): 5078. https://dx.doi.org/10.3390/ijms26115078
  9. Kim Y., Cho M.K., Chung Y.J., Hong S.H., Hwang K.R., Jeon G.H. et al.; Publication Committee on Clinical Guidelines of the Korean Society of Menopause. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J. Menopausal Med. 2025; 31(2): 53-84. https://dx.doi.org/10.6118/jmm.25103
  10. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028
  11. European Menopause and Andropause Society (EMAS). EMAS statement on the FDA decision to remove “Black Box” warnings from Menopausal Hormone Therapy (MHT). Available at: https://www.linkedin.com/pulse/emas-statement-fda-decision-remove-cpmgf
  12. https://edition.cnn.com/2025/10/02/health/menopause-hrt-warning-change-makary
  13. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213
  14. Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5): 426-46. https://dx.doi.org/10.1080/13697137.2020.1804547
  15. Li X.T., Li P.Y., Liu Y., Yang H.S., He L.Y., Fang Y.G. et al. Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis. Qual Life Res. 2020; 29(1):19-36. https://dx.doi.org/10.1007/s11136-019-02326-2
  16. Honigberg M.C., Zekavat S.M., Aragam K., Finneran P., Klarin D., Bhatt D.L. et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019; 322(24): 2411-21. https://dx.doi.org/10.1001/jama.2019.19191
  17. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8. [Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Obstetrics and Gynecology. 2023; (5): 50-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.16
  18. https://www.who.int/ru/initiatives/decade-of-healthy-ageing
  19. Mansour D., Barber K., Chalk G., Noble N., Digpal A.A.S., Talaulikar V. et al. The evolving perspective of menopause management in the United Kingdom. Womens Health (Lond). 2024; 20: 17455057241288641. )]. https://dx.doi.org/10.1177/17455057241288641
  20. Наделяева Я.Г., Данусевич И.Н. Особенности менопаузы, осведомленность и качество жизни женщин, проживающих в городской и сельской местности. Доктор.Ру. 2025; 24(1): 81-7. [Nadeliaeva Ia.G., Danusevich I.N. Specifics of menopause, awareness and quality of life of women living in urban and rural areas. Doctor.Ru. 2025; 24(1): 81-7 (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2025-24-1-81-87
  21. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and climacteric state in women. 2025. (in Russian)].
  22. El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020; 142(25): e506-e532. https://dx.doi.org/10.1161/CIR.0000000000000912
  23. Stuenkel C.A. Reproductive milestones across the lifespan and cardiovascular disease risk in women. Climacteric. 2024; 27(1): 5-15. https://dx.doi.org/10.1080/13697137.2023.2259793
  24. Thurston R.C., Aslanidou Vlachos H.E., Derby C.A., Jackson E.A., Brooks M.M., Matthews K.A. et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J. Am. Heart Assoc. 2021; 10(3): e017416. https://dx.doi.org/10.1161/JAHA.120.017416
  25. Boardman H.M., Hartley L., Eisinga A., Main C., Roqué i Figuls M., Bonfill Cosp X. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015; 2015(3): CD002229. https://dx.doi.org/10.1002/14651858.CD002229.pub4
  26. Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409. https://dx.doi.org/10.1136/bmj.e6409
  27. Johansson T., Karlsson T., Bliuc D., Schmitz D., Ek W.E., Skalkidou A. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024; 387: e078784. https://dx.doi.org/10.1136/bmj-2023-078784
  28. Oliver-Williams C., Glisic M., Shahzad S., Brown E., Pellegrino Baena C., Chadni M. et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum. Reprod. Update. 2019; 25(2): 257-71. https://dx.doi.org/10.1093/humupd/dmy039
  29. Kalenga C.Z., Metcalfe A., Robert M., Nerenberg K.A., MacRae J.M., Ahmed S.B. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study. Hypertension. 2023; 80(7):1463-73. https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19938
  30. Cho L., Kaunitz A.M., Faubion S.S., Hayes S.N., Lau E.S., Pristera N. et al.; ACC CVD in Women Committee. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation. 2023; 147(7): 597-610. https://dx.doi.org/10.1161/CIRCULATIONAHA.122.061559
  31. Mueck A.O., Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005; 3(1): 45-54. https://dx.doi.org/10.2174/1568016052773270
  32. Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32. [Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association. Obstetrics and Gynecology. 2023; (11): 211-32 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.267
  33. Straczek C., Oger E., Yon de Jonage-Canonico M.B., Plu-Bureau G., Conard J., Meyer G. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22): 3495-500. https://dx.doi.org/10.1161/CIRCULATIONAHA.105.565556
  34. Olié V., Canonico M., Scarabin P.Y. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr. Opin. Hematol. 2010; 17(5): 457-63. https://dx.doi.org/10.1097/MOH.0b013e32833c07bc
  35. Mohammed K., Abu Dabrh A.M., Benkhadra K., Al Nofal A., Carranza Leon B.G., Prokop L.J. et al. Oral vs Transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2015; 100(11): 4012-20. https://dx.doi.org/10.1210/jc.2015-2237
  36. Зотова И.В., Затейщиков Д.А. Наследственная тромбофилия и венозные тромбоэмболические осложнения: правила тестирования в клинической практике. Российский кардиологический журнал. 2020; 25(3S): 4024. [Zotova I.V., Zateyshchikov D.A. Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice. Russian Journal of Cardiology. 2020; 25(3S): 4024 (in Russian)]. https://dx.doi.org/10.15829/1560-4071-2020-4024
  37. Dicks A.B., Moussallem E., Stanbro M., Walls J., Gandhi S., Gray B.H. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J. Clin. Med. 2024; 13(2): 362. https://dx.doi.org/10.3390/jcm13020362
  38. Rovinski D., Ramos R.B., Fighera T.M., Casanova G.K., Spritzer P.M. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb. Res. 2018; 168: 83-95. https://dx.doi.org/10.1016/j.thromres.2018.06.014
  39. Royal College of Obstetricians & Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: Acute management. Green-top Guideline No. 37b. London: RCOG; 2015.
  40. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2018; 132(1): e18-e34. https://dx.doi.org/10.1097/AOG.0000000000002703
  41. Alnor A.B., Gils C., Vinholt P.J. Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis. Ann. Hematol. 2024; 103(10): 4285-94. https://dx.doi.org/10.1007/s00277-024-05926-2
  42. Canonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008; 336(7655): 1227-31. https://dx.doi.org/10.1136/bmj.39555.441944.BE
  43. Folsom A.R., Aleksic N., Wang L., Cushman M., Wu K.K., White R.H. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler. Thromb. Vasc. Biol. 2002; 22(6): 1018-22. https://dx.doi.org/10.1161/01.atv.0000017470.08363.ab
  44. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet. Gynecol. 2013; 121(4): 887-90. https://dx.doi.org/10.1097/01.AOG.0000428645.90795.d9
  45. https://thebms.org.uk/wp-content/uploads/2025/04/09-BMS-TfC-NICE-Menopause-Menopause-identification-and-management-%E2%80%93-from-guideline-to-practice-MARCH2025-D.pdf
  46. Lumsden M.A., Dekkers O.M., Faubion S.S., Lindén Hirschberg A., Jayasena C.N., Lambrinoudaki I. et al. European society of endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur. J. Endocrinol. 2025; 193(4): G49-G81. https://dx.doi.org/10.1093/ejendo/lvaf206
  47. Asmis L., Hellstern P. Thrombophilia testing - a systematic review. Clin. Lab. 2023; 69(4). https://dx.doi.org/10.7754/Clin.Lab.2022.220817
  48. Douketis J.D., Julian J.A., Kearon C., Anderson D.R., Crowther M.A., Bates S.M. et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J. Thromb. Haemost. 2005; 3(5): 943-8. https://dx.doi.org/10.1111/j.1538-7836.2005.01268.x
  49. Middeldorp S., Nieuwlaat R., Baumann Kreuziger L., Coppens M., Houghton D., James A.H. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023; 7(22): 7101-38. https://dx.doi.org/10.1182/bloodadvances.2023010177
  50. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5. https://dx.doi.org/10.1161/CIRCULATIONAHA.106.642280
  51. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. https://dx.doi.org/10.1136/bmj.k4810
  52. Hicks A., Robson D., Tellis B., Smith S., Dunkley S., Baber R. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025; 28(5): 497-509. https://dx.doi.org/10.1080/13697137.2025.2503874
  53. Renoux C., Dell'Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86. https://dx.doi.org/10.1111/j.1538-7836.2010.03839.x
  54. Canonico M., Fournier A., Carcaillon L., Olié V., Plu-Bureau G., Oger E. et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5. https://dx.doi.org/10.1161/ATVBAHA.109.196022
  55. Sweetland S., Beral V., Balkwill A., Liu B., Benson V.S., Canonico M. et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012; 10(11): 2277-86. https://dx.doi.org/10.1111/j.1538-7836.2012.04919.x
  56. Manson J.E., Kaunitz A.M. Menopause management--getting clinical care back on track. N. Engl. J. Med. 2016; 374(9): 803-6. https://dx.doi.org/10.1056/NEJMp1514242
  57. Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018; 21(4): 346-54. https://dx.doi.org/10.1080/13697137.2018.1455657
  58. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166
  59. Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F. et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022; 163: 1-14. https://dx.doi.org/10.1016/j.maturitas.2022.04.008
  60. Menopause: identification and management. London: National Institute for Health and Care Excellence (NICE); 2024 Nov 7.
  61. Genazzani A.R., Divakar H., Khadilkar S.S., Monteleone P., Evangelisti B., Galal A.F. et al. Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int. J. Gynaecol. Obstet. 2024; 164(2): 516-30. https://dx.doi.org/10.1002/ijgo.15278
  62. Ayzenberg I., Katsarava Z., Sborowski A., Chernysh M., Osipova V., Tabeeva G. et al.; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012; 32(5): 373-81. https://dx.doi.org/10.1177/0333102412438977
  63. Welch K.M., Brandes J.L., Berman N.E. Mismatch in how oestrogen modulates molecular and neuronal function may explain menstrual migraine. Neurol. Sci. 2006; 27 Suppl 2: S190-2. https://dx.doi.org/10.1007/s10072-006-0599-6
  64. Ravi V., Osouli Meinagh S., Bavarsad Shahripour R. Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk. Front. Neurol. 2024; 15: 1435208. https://dx.doi.org/10.3389/fneur.2024.1435208
  65. Scottish Government Women’s Health and Heart Health Policy Teams with thanks to the numerous clinicians who helped and in collaboration with the medical advisory council of the British Menopause Society. Management of menopause for women with cardiovascular disease. Post Reprod. Health. 2024; 30(4): 280-4. https://dx.doi.org/10.1177/20533691241302040
  66. Ali N., Sohail R., Jaffer S.R., Siddique S., Kaya B., Atowoju I. et al. The role of estrogen therapy as a protective factor for Alzheimer's disease and dementia in postmenopausal women: a comprehensive review of the literature. Cureus. 2023; 15(8): e43053. https://dx.doi.org/10.7759/cureus.43053
  67. Maki P.M., Jaff N.G. Brain fog in menopause: A health-care professional's guide for decision-making and counseling on cognition. Climacteric. 2022; 25(6): 570-8. https://dx.doi.org/10.1080/13697137.2022.2122792
  68. Garber J.R., Cobin R.H., Gharib H., Hennessey J.V., Klein I., Mechanick J.I. et al.; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012; 22(12): 1200-35. https://dx.doi.org/10.1089/thy.2012.0205
  69. Mintziori G., Veneti S., Poppe K., Goulis D.G., Armeni E., Erel C.T. et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024; 185: 107991. https://dx.doi.org/10.1016/j.maturitas.2024.107991
  70. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гипотиреоз. 2025. [Ministry of Health of the Russian Federation. Clinical guidelines. Hypothyroidism. 2025. (in Russian)].
  71. Kaminski J., Junior C.M., Pavesi H., Drobrzenski B., Amaral G.M.D. Effects of oral versus transdermal estradiol plus micronized progesterone on thyroid hormones, hepatic proteins, lipids, and quality of life in menopausal women with hypothyroidism: a clinical trial. Menopause. 2021; 28(9): 1044-52. https://dx.doi.org/10.1097/GME.0000000000001811
  72. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92(2): 399-404. https://dx.doi.org/10.1210/jc.2006-0513
  73. International Diabetes Federation. Diabetes Atlas. 11th Edition – 2025. Available at: https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025-1.pdf
  74. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204-21. [Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021; 24(3): 204-21. (in Russian)]. https://dx.doi.org/10.14341/DM12759
  75. Rossi R., Origliani G., Modena M.G. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care. 2004; 27(3): 645-9. https://dx.doi.org/10.2337/diacare.27.3.645
  76. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006; 8(5): 538-54. https://dx.doi.org/10.1111/j.1463-1326.2005.00545.x
  77. WHO. Obesity and overweight. 8 December 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  78. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403(10431): 1027-50. https://dx.doi.org/10.1016/S0140-6736(23)02750-2
  79. Giannini A. Menopause, hormone replacement therapy (HRT) and obesity. Curr. Res. Diab. Obes. J. 2018; 7(1): 555704. https://dx.doi.org/10.19080/CRDOJ.2018.07.555704
  80. Powell-Wiley T.M., Poirier P., Burke L.E., Després J.P., Gordon-Larsen P., Lavie C.J. et al.; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021; 143(21): e984-e1010. https://dx.doi.org/10.1161/CIR.0000000000000973
  81. Hotoleanu C. Association between obesity and venous thromboembolism. Med. Pharm. Rep. 2020; 93(2):162-8. https://dx.doi.org/10.15386/mpr-1372
  82. Beaudart C., Zaaria M., Pasleau F., Reginster J.Y., Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017; 12(1): e0169548. https://dx.doi.org/10.1371/journal.pone.0169548
  83. Palacios S., Chedraui P., Sánchez-Borrego R., Coronado P., Nappi R.E. Obesity and menopause. Gynecol. Endocrinol. 2024; 40(1): 2312885. https://dx.doi.org/10.1080/09513590.2024.2312885
  84. O'Sullivan A.J., Crampton L.J., Freund J., Ho K.K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 1998; 102(5): 1035-40. https://dx.doi.org/10.1172/JCI2773
  85. Mukherjee A., Ghaem-Maghami S., Syed A.A. Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reprod. Health. 2025; 31(2): 127-31. https://dx.doi.org/10.1177/20533691251343069
  86. Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1): 230. https://dx.doi.org/10.1186/s12877-017-0621-2
  87. Суджаева О.А. Проблема полипрагмазии при лечении сердечно-сосудистых заболеваний у лиц пожилого возраста: обзор Консенсуса экспертов рабочей группы Европейского общества кардиологов. Медицинские новости. 2022; 5: 20-6. [Sujayeva O.A. The problem of polypharmacy in the treatment of cardiovascular diseases in the elderly: a review of the expert consensus of the working group of the European Society of Cardiology. Meditsinskie novosti. 2022; 5: 20-6 (in Russian)].
  88. Gosselin M., Talbot D., Simard M., Chiu Y.M., Mésidor M., Boiteau V. et al. Classifying polypharmacy according to pharmacotherapeutic and clinical risks in older adults: a latent class analysis in Quebec, Canada. Drugs Aging. 2023; 40(6): 573-83. https://dx.doi.org/10.1007/s40266-023-01028-2
  89. Юренева С.В. Менопаузальная гормональная терапия – индивидуализированный подход с позиции эффективности и безопасности: обзор международных рекомендаций. Акушерство и гинекология. 2024; 9: 36-46. [Yureneva S.V. Efficacy and safety of personalized menopausal hormone therapy: a review of international guidelines. Obstetrics and Gynecology. 2024; (9): 36-46 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.224
  90. Rodriguez S., Gaunt T.R., Guo Y., Zheng J., Barnes M.R., Tang W. et al. Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array. Eur. J. Hum. Genet. 2016; 24(1): 106-12. https://dx.doi.org/10.1038/ejhg.2015.63
  91. Cirillo D.J. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330. https://dx.doi.org/10.1001/jama.293.3.330
  92. Liu B., Beral V., Balkwill A., Green J., Sweetland S., Reeves G.; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008; 337: a386. https://dx.doi.org/10.1136/bmj.a386
  93. Saddique M.N., Saleem S., Shahid I., Javid S., Hamza Khan M., Iqbal J. The estrogen‑gallstone connection: uncovering the pathways. Discov. Public Health. 2024; 21: 113. https://dx.doi.org/10.1186/s12982-024-00232-8

Similar Articles

№12 / 2025
Yureneva S.V., Averkova V.G.
Comorbid anxiety in women with menopause of various etiology
№5 / 2024
Ramazanova М.О., Apolikhina I.A., Shershakova E.I.
Modern problems and opportunities in the treatment of genitourinary syndrome of menopause in the context of medical science and technology development
№6 / 2024
Stenyaeva N.N., Khritinin D.F., Stenyaev E.Yu.
Experience of using a combined melatonin-containing drug in the correction of sleep disorders in women
№6 / 2024
Yashchuk A.G., Dautova L.A., Shaikhutdinova O.V., Muslimova L.R., Berg P.A., Berg E.A., Nasyrova S.F., Kizko I.A., Nazyrova A.G.
Possibilities of the biologically active complex of phytopreparations in the correction of menopausal disorders
№3 / 2025
Andreeva E.N., Yureneva S.V., Yarmolinskaya M.I.
Additional benefits of menopausal hormone therapy with drospirenone for healthy longevity
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.